Hims & Hers won’t sell compounded version of Novo’s obesity pill

Hims & Hers stated Saturday it’s going to cease promoting what it claims to be a less expensive, compounded model of Novo Nordisk’s weight problems capsule on its telehealth platform, after well being officers referred to as for an investigation of the corporate for probably violating federal legislation.

Hims launched the compounded drug earlier this week at $49 month. That prompted instant backlash from Novo, which had launched the capsule, the oral model of its injectable Wegovy remedy, final month at $149 to $299 a month. The mass manufacturing of copies of a brand-name drug is often solely allowed when the drug is in scarcity. 

STAT Plus: HHS asks Justice Division to probe Hims & Hers over its cheaper compounded model of Wegovy

Quickly after, the Meals and Drug Administration stated it could take “decisive steps” to thwart firms resembling Hims which can be mass advertising and marketing unapproved, compounded variations of GLP-1 medication. Then on Friday, the Division of Well being and Human Companies requested the Division of Justice to research Hims.